Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Abivax SA Sponsored ADR ( (ABVX) ).
On June 6, 2025, Abivax SA held its annual general meeting of shareholders, where all proposed resolutions were adopted, including the approval of the 2024 financial statements and the compensation policy for key executives. The meeting also ratified the appointments of Sylvie Grégoire as Chairman and Dominik Höchli as a Board member, indicating strong shareholder support for the company’s strategic direction.
The most recent analyst rating on (ABVX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Abivax SA Sponsored ADR stock, see the ABVX Stock Forecast page.
Spark’s Take on ABVX Stock
According to Spark, TipRanks’ AI Analyst, ABVX is a Neutral.
The overall stock score for Abivax SA is 53, primarily driven by significant financial challenges characterized by consistent operational losses and negative cash flows. While the stock shows positive short-term momentum, it is tempered by overbought technical indicators. The valuation is weak due to a negative P/E ratio and lack of dividend yield, making the stock less attractive.
To see Spark’s full report on ABVX stock, click here.
More about Abivax SA Sponsored ADR
Abivax SA is a clinical-stage biotechnology company that focuses on developing therapeutics to stabilize the immune response in patients with chronic inflammatory diseases. The company is based in France and the United States, with its lead drug candidate, obefazimod (ABX464), currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Average Trading Volume: 212,181
Technical Sentiment Signal: Hold
Current Market Cap: $481.9M
See more data about ABVX stock on TipRanks’ Stock Analysis page.